Visual impairment in children with a brain tumor in the Netherlands: a prospective nationwide study using standard visual testing and optical coherence tomography

Visual impairment in children with a brain tumor in the Netherlands: a prospective nationwide study using standard visual testing and optical coherence tomography - KIZZ study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49033

Enrollment

170

Registered

2019-04-24

Start date

2019-05-15

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual decline visual impairment

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: - All children, 0-18 years with any type of brain tumor - Informed and having given informed consent (either by patient and / or parents / legal guardian)

Exclusion criteria

Exclusion criteria: - Refusal by patient and / or parent / legal guardian

Design outcomes

Primary

Measure	Time frame
Main outcome measures are visual acuity (VA) (LogMar results), visual field (VF) (results of BEFIE/Humphrey peritest/non-automated static peritest/goldmann perimetrie) and changes in OCT parameters (RNFL thickness and GCL-ILP).	—

Secondary

Measure	Time frame
Secondary outcome parameters include visual decline (measured by the above-mentioned primary endpoints), disease status (findings on MRI) and treatment characteristics (type/frequency/dose). Expected variables at baseline are: Age, gender, ethnicity, medical (including ophthalmologic) history, neurofibromatosis 1 (yes/no), brain tumor type (histology), tumor location, tumor size and presence/absence of hydrocephalus and/or metastases. Tertiary outcome parameters include generic and cancer-specific HRQoL (measured by the Pediatric Quality of Life Inventory (PedsQL) Generic and Cancer scales) and vision-related HRQol (measured by the Participation and Activity Inventory for Children and Youth (PAI-CY)).	—

Measure

Time frame

Secondary outcome parameters include visual decline (measured by the above-mentioned primary endpoints), disease status (findings on MRI) and treatment characteristics (type/frequency/dose). Expected variables at baseline are: Age, gender, ethnicity, medical (including ophthalmologic) history, neurofibromatosis 1 (yes/no), brain tumor type (histology), tumor location, tumor size and presence/absence of hydrocephalus and/or metastases. Tertiary outcome parameters include generic and cancer-specific HRQoL (measured by the Pediatric Quality of Life Inventory (PedsQL) Generic and Cancer scales) and vision-related HRQol (measured by the Participation and Activity Inventory for Children and Youth (PAI-CY)).

—

Countries

Netherlands

Outcome results